The chronic rhinosinusitis with nasal polyp patient journey in the United States and Europe

Jeremiah Hwee; Lauren Lee; Mark Small; Steven G Smith; Victoria S Benson; Shiyuan Zhang

doi:10.1186/s13223-024-00879-7

The chronic rhinosinusitis with nasal polyp patient journey in the United States and Europe

Allergy Asthma Clin Immunol. 2024 Feb 26;20(1):17. doi: 10.1186/s13223-024-00879-7.

Authors

Jeremiah Hwee¹, Lauren Lee², Mark Small², Steven G Smith³, Victoria S Benson⁴, Shiyuan Zhang⁵

Affiliations

¹ Value Evidence and Outcomes, GSK, Mississauga, ON, Canada. jeremiah.x.hwee@gsk.com.
² Adelphi Real World, Bollington, Cheshire, UK.
³ Clinical Sciences, GSK, Durham, NC, USA.
⁴ Epidemiology, Value Evidence and Outcomes, GSK, Brentford, Middlesex, UK.
⁵ Value Evidence and Outcomes, GSK, Collegeville, PA, USA.

Abstract

In this letter to the editor, we present questionnaire-based data assessing the patient journey of adults with moderate-severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in the USA and five European countries. These data highlight how long and difficult the patient journey with CRSwNP can be and how improved disease awareness among physicians could lead to more timely diagnosis and treatment, and hence improved management of patients.

Keywords: Chronic Rhinosinusitis; Nasal polyps; Quality of life; Smell.

Publication types

Letter

Grants and funding

Study Numbers: 208086 and 213369/GSK